Zicronapine (Schizophrenia) Market Size, Growth & Forecast Report 2022: Radiant Insights, Inc
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide.
While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/zicronapine-schizophrenia-forecast-and-market-analysis-to-2022
Zicronapine is a D1, D2, and 5-HT2A receptor antagonist in development by Lundbeck. Zicronapine preferentially binds to D1 receptors over D2 and it has a unique affinity for other monoamine receptors, rendering a theoretical utility in psychosis, schizophrenia, and other conditions in which pro-cognitive agents may be useful.
- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Zicronapine including product description, safety and efficacy profiles as well as a SWOT analysis.